www.kxvo.com/story/20274160/eylea-aflibercept-submitted-for-eu-marketing-authorization-for-the-treatment-of-macular-edema-following-central-retinal-vein-occlusion

<body> <p>Please visit our site at <a href="http://www.cw15kxvo.com/story/20274160/eylea-aflibercept-submitted-for-eu-marketing-authorization-for-the-treatment-of-macular-edema-following-central-retinal-vein-occlusion">http://www.cw15kxvo.com/story/20274160/eylea-aflibercept-submitted-for-eu-marketing-authorization-for-the-treatment-of-macular-edema-following-central-retinal-vein-occlusion</a>.</p> <script type="text/javascript">if(!NREUMQ.f){NREUMQ.f=function(){NREUMQ.push(["load",new Date().getTime()]);var e=document.createElement("script");e.type="text/javascript";e.src=(("http:"===document.location.protocol)?"http:":"https:")+"//"+"d1ros97qkrwjf5.cloudfront.net/42/eum/rum.js";document.body.appendChild(e);if(NREUMQ.a)NREUMQ.a();};NREUMQ.a=window.onload;window.onload=NREUMQ.f;};NREUMQ.push(["nrfj","beacon-1.newrelic.com","12f1b6872c","769899","ZwdaZEQEV0RUURJZDl5NbUJfSk5SV1UTWQVZDF8eRg1J",0,3,new Date().getTime(),"","","","",""]);</script> </body>